(Q34368959)

English

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

Antonio Bertolotto

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Matthias Mehling

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Xavier Montalban

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Finn Sellebjerg

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Per Soelberg Sørensen

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

H Hegen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

A Millonig

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

M Comabella

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

G Giovanonni

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

M Guger

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

M Hoelzl

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

M Khalil

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

J Killestein

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

R Lindberg

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

S Malucchi

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

C H Polman

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

D Rudzki

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

F Schautzer

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

F Deisenhammer

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

5 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

577-587

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

The human intracellular Mx-homologous protein is specifically induced by type I interferons.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Comparative study of four different assays for the detection of binding antibodies against interferon-beta

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Anti-IFN BAb and NAb antibodies: a minireview

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Interferon-β antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1177%2F1352458513503597

21 January 2018

Identifiers

10.1177/1352458513503597

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24009164%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34368959&oldid=1641158964"